Hologic’s Stock Up 20% On Mammography Study Results; OTC Index Flat
This article was originally published in The Gray Sheet
Executive Summary
Medical imaging systems maker Hologic's shares surged nearly 14% to $53.44 on Sept. 16 after the New England Journal of Medicine posted study results showing that digital mammography has superior diagnostic accuracy than film in a subset of women
You may also be interested in...
Digital Mammography’s Cost May Outweigh Benefits – NEJM Editorial
Conversion from film to digital mammography, despite benefits for segments of the population, may not be practical or cost-effective, according to a recent editorial in the New England Journal of Medicine
Digital Mammography’s Cost May Outweigh Benefits – NEJM Editorial
Conversion from film to digital mammography, despite benefits for segments of the population, may not be practical or cost-effective, according to a recent editorial in the New England Journal of Medicine
Possis Aims To Reverse AngioJet Losses With JETSTENT Trial
Possis views its upcoming 500-patient JETSTENT trial as the final step in a three-part plan to overcome the damaging results of its 2004 AiMI study and recover lostAngioJet thrombectomy system sales